Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000435885 | SCV000521082 | likely pathogenic | not provided | 2016-06-23 | criteria provided, single submitter | clinical testing | The G321D likely pathogenic variant in the COL3A1 gene has been reported in association with EDS type IV (Pepinet al., 2014). In a cohort of 572 EDS type IV index patients harboring an underlying heterozygous COL3A1 variant, G321D was identified in one individual (Pepin et al, 2014). Moreover, the G321D variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The G321D variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In addition, this substitution occurs at a position that is conserved across species. Consequently, in silico analysis predicts this variant is probably damaging to the protein structure/function. The G321D variant affects a Glycine residue in a Gly-X-Y motif in the triple helical region of the COL3A1 gene, where the majority of pathogenic missense variants occur (Stenson et al., 2014; Symoens et al., 2012). Furthermore, Pepin et al. (2014) reported that EDS type IV patients harboring missense variants in which Aspartic acid is substituted for Glycine within the triple helical region of COL3A1 have a decreased life expectancy compared to individuals with COL3A1 null variants (Hazard Ratio = 5.3). Finally, a missense variant in the same residue (G321V) has been reported in the Human Gene Mutation Database in association with EDS type IV (Stenson et al., 2014); however, the pathogenicity of this variant has not been definitively determined. Therefore, this variant is likely pathogenic. In order to definitively determine its clinical significance, additional data is required. |
| Labcorp Genetics |
RCV000087628 | SCV000756056 | pathogenic | Ehlers-Danlos syndrome, type 4 | 2017-10-24 | criteria provided, single submitter | clinical testing | Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, missense variants at these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. This variant has been reported in an individual affected with vascular Ehlers–Danlos syndrome (PMID: 24922459). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with aspartic acid at codon 321 of the COL3A1 protein (p.Gly321Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. |
| Collagen Diagnostic Laboratory, |
RCV000087628 | SCV000120519 | pathogenic | Ehlers-Danlos syndrome, type 4 | no assertion criteria provided | clinical testing |